James Bicher MD,
Founder and Director of Bicher Cancer Institute
Answer/Response to Stephen Barrett MD
Stephen Barrett, MD is an unlicensed psychologist who
dedicates his life to criticize, defamate (from defamation), and "try" very hard
to ruin Alternative and Complementary doctors and practitioners reputation in
the internet, with no much success.
He is the creator and also maintain the disgraceful famous
websites, casewatch.org, and quackwatch.org. We all know that people are famous
for two things: when you are good and help your fellow human beings, or when you
are so sick, twisted, and have such bad intentions AGAINST your fellow human
beings. I do not need to tell you where you will include Stephen Barrett.
Dr James I. Bicher have been investigated by the Medical
Board of California regarding a complaint that a relative of one of his patients
As you might know, any patient can go to a medical board
of any state and file a complain for any thing she/he believes is not right
regarding the treatment received at her/his doctor.
The medical board "HAS THE OBLIGATION TO ACT UPON ANY
COMPLAIN" and determine if the it is correct or not. On the process, the medical
board will issue an "Accusation". The accusation is in place and public until
the situation is resolved.
In Dr James Bicher MD case, the board found some medical
bookkeeping deficiencies, and put Dr Bicher on 5 years probation. After three
years of probation, Dr Bicher appealed the medical board decision and the
probation was lifted, on November 19, 2009.
After the decision of the medical board to terminate Dr
Bicher's probation, Stephen Barrett continues to maliciously post the old
medical board accusation and early decision, but he does not clearly states that
Dr Bicher's medical situation with the medical board has been clear.
You can make your own conclusion by browsing "Stephen
Barrett MD" and also reading any of his websites, and find out for your self if
there is any value on what Stephen Barrett is doing to make his living. I will
suggest him to start doing something that help ANYBODY and make a decent living
If you have any question, you can reach me at
310-398-0013, or email me at email@example.com.
Thanks for reading this post.
Carlos D Caridad
Vice President Internet Marketing
Valley Cancer Institute
Bicher Cancer Institute
approved Alternative Cancer Treatment
Dr James Bicher MD has been researching and clinically
treating cancer patients, in the Hyperthermia field, since 1982. At that
time James Bicher MD joined Western Tumor Medical Group, in Van
Nuys , California. He founded Valley Cancer Institute in 1985, where he
has been practicing Radiation Oncology and Hyperthermia, to the present.
Today, in his facility in Culver City, Los Angeles area, California, Dr. James
Bicher's institute provides 6 Hyperthermia treatment rooms, and a fully
equipped Radiation Department, including an IMRT device. Hyperthermia and IMRT
are a very successful combination to treat many kind of tumors, spearing normal
tissues. IMRT is a Radiation technique, that focuses radiation therapy to target
only the tumor, avoiding surrounded areas as much as possible (definitely much
more than conventional radiation). The Valley Cancer Institute clinic has the
capacity of treating about 50 patients a day, making it the largest Hyperthermia
facility in the US and on of the largest of the world.
Dr. James Bicher MD protocol has been very successful treating breast cancer,
prostate cancer, head and neck cancer, and other tumors locations.
Bicher Cancer Institute, formerly known as Valley Cancer Institute, has been operating in Culver City, California for about
19 years, since November 1989.
Dr James Bicher is opening a second clinic named Bicher Cancer Institute in
Beverly Hills, in middle 2010.
Dr James I. Bicher in front of his new Clinic in 455 N. Roxbury Dr, Beverly
Hills 90210, to be open soon
The Role of Local Blood Flow, Rheological Properties and Free Radicals
in Hyperthermia-Induced in Cerebral Tissue Damage
I. Bicher, Nodar P. Mitagvaria*, Marina I. Nebieridze*
Cancer Institute, Los Angeles, California, USA
*Beritashvili Institute of Physiology, Georgian Academy of Sciences,
Objective. We tried
the sensitivity of cerebral tissue to hyperthermia as manifested by
histological changes and
the role of local blood flow, blood rheological properties, and free
radicals in development of mentioned changes.
.Research design and methods. Local
areas of cerebral surface were irrigated by artificial cerebrospinal
fluid heated up to the temperature necessary for
achievement of stable level of temperature (41, 43 or 450C).
Serial brain coronal sections 50 mm
thick stained with Azure-Eosin were analyzed under light microscope. The
local cerebral blood flow was measured by thermal clearance method.
Blood rheological properties were changed by injection of high molecular
weight Dextran T-500 and free radicals existence was controlled by
Dimethyl sulfoxide injection.
At 410C just superficial
lesions of the cerebral cortex and a few cases of thrombosed cerebral
microvessels have been observed. The rise of temperature on 20C
resulted in very severe lesions of cerebral tissue; the layered
structure of the cerebral cortex in the central parts of the
hyperthermia–induced lesions was impaired. The highest temperature (450C)
caused complete destruction of the layered structure of the cortex in
the area of hyperthermic exposure, numerous areas with lost neurons and
thrombosed cerebral vessels with perivascular accumulation of
erythrocytes were revealed. Injection of Dextran T-500 resulted in
deterioration and injection of Dimethyl sulfoxide in significant
improvement of histological changes in cerebral tissue when 43 or 450C
hyperthermia is used. Bi-phase alterations of local cerebral blood flow
have been revealed at 430C hyperthermia. Pronounced hyperemia
in first stage of heating is followed by remarkable ischemia on the late
High sensitivity of cerebral tissue to
hyperthermic exposure has been confirmed. We can
consider cerebrovascular thrombosis as one of the most significant
complication of brain hyperthermia. In case of deteriorated blood
rheological properties hyperthermia-induced cerebral lesion is more
remarkable. Administration of antioxidants, scavengers of free radicals
can partially lessen hyperthermia induced cerebral lesion.
A Method of Curative Thermoradiotherapy in Superficial Tumors;
Breast, Head and Neck, and Prostate
James I. Bicher, M.D., and Ralph S.
Valley Cancer Institute, Los Angeles, California U.S.A.
Objective: To evaluate the effectiveness of hyperfractionated
thermoradiotherapy (HTRT) in patients suffering from early stage cancers
of the breast, head and neck and prostate that refuse conventional
radiation surgery or chemotherapy. Response rates and survival were
determined using objective end points. (MRI, MRS, PET scan and tumor
Material and Methods:
Fractionation used involved daily hyperthermia treatments in conjunction
with each radiation fraction. Radiation daily doses are progressively
decreased from 180 to 100 cGy resulting in protracted treatment time
that decreases the isoeffect biological equivalent dose by 15% to 25%.
This decrease is compensated by the increased number of hyperthermia
fractions which potentiates each radiation dose. Treatment is continued
until an objective complete response is attained, or failure
determined. 40 breast patients, 27 head and neck and 18 prostate
patients were treated with a follow up of two to five years. All
patients were early stage (less than III).
Complete response rates were 82% for breast patients, 88% for head and
neck and 93% for prostate patients. Projected 5 year survival rates
were 80% for breast patients, 88% for head and neck, and 87% for
prostate patients. Side effects were less than with curative radiation
therapy alone. No Grade IV toxicity (Common Toxicity Criteria) was
Protracted hyperfractionation of daily thermoradiotherapy decreases the
side effects of radiation therapy, allows treating to effect using
objective end point parameters, accomplishes a high percentage of
complete responses and a high 5-year survival rate in the 80-90% range
in early superficial tumors. It can be considered as potentially
curative in Stage I-II breast, head and neck and prostate cancer when
used and researched as such.
Dr. James Bicher (Haim Bicher, M.D.) presented
two papers at the ICHS Meeting: ... Haim Bicher MD Hyperthermia Breast Cancer Treatment
James Haim Bicher MD... www.zoominfo.com/people/Bicher_Haim_26543077.aspx